Potential impact of takeda's dengue vaccine candidate reinforced by long-term safety and efficacy results

Osaka, japan & cambridge, mass.--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that its dengue vaccine candidate (tak-003) demonstrated continued protection against dengue illness and hospitalization, regardless of an individual's previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal phase 3 tetravalent immunization against dengue efficacy study (tides) trial. tides
TAK Ratings Summary
TAK Quant Ranking